MycoBiomDB – Record Details (MyCo_1605)

Biomarker Record Details

Database ID: MyCo_1605
DB IDMyCo_1605
TitleDetection of urinary excreted fungal galactomannan-like antigens for diagnosis of invasive aspergillosis
Year2012
PMID22900046
Fungal Diseases involvedInvasive aspergillosis
Associated Medical ConditionNone
GenusAspergillus
Speciesfumigatus
OrganismAspergillus fumigatus
Ethical StatementMouse experiments were conducted at the Albert Einstein College of Medicine, Bronx, NY, following a protocol approved by the Institutional Animal Care and Use Committee (IACUC) of that institution (Protocol number: 20090404); imaging procedures were performed under isofluorane anesthesia according to protocol. Experiments with the Guinea Pig model of invasive aspergillosis were conducted at the San Antonio Center for Medical Mycology of the University of Texas Health Science Center, following protocols approved by IACUC (Protocol number: 00101G). All studies involving human urine samples were approved by the Johns Hopkins Medicine Institutional Review Board (IRB) (collection of urine from consented human volunteers, study number: NA_00029178; use of previously collected, de-identified, banked urine samples, study number: NA_00027228); written consent forms are in file.
Site of InfectionNone
Opportunistic invasiveOpportunistic
Sample typeBody fluid
Sample sourceSerum
Host GroupAnimal
Host Common nameMice
Host Scientific nameMus musculus
Biomarker NameGM-reactive MAb476
Biomarker Full NameGalactomannan-reactive Monoclonal Antibody 476
Biomarker TypeDiagnostic
BiomoleculeProtein
Geographical LocationUSA
CohortBriefly, serum, broncho-alveolar lavage fluid (BAL) and lungs were collected, at day 2 post-aerosol infection, from A. fumigates (strain 90906)-infected neutropenic C57BL/6 mice.
Cohort No.None
Age GroupNone
P ValueNone
SensitivityNone
SpecificityNone
Positive Predictive ValueNone
MICNone
Fold ChangeNone
PathwayNone
Disease Introduction MechanismMortality associated with invasive aspergillosis (IA) is high despite availability of potent antifungal drugs. Delayed diagnosis partly contributes to this poor outcome, since classical microbiological methods are insensitive. Culture-independent detection of several fungal components have shown promise for earlier diagnosis.
TechniqueELISA
Analysis MethodELISA Based
ELISA kits‘GM-EIA’ Platelia Aspergillus EIA, BioRad Inc., Hercules, CA.
Assay DataNone
Validation Techniques usedELISA, LFD
Up Regulation Down RegulationNone
Sequence DataNone
External LinkNone